The European Medicines Agency (EMA) published all Committee for Medicinal Products for Human Use (CHMP) evaluations for 2025, offering valuable insight into the latest EU medicine approvals, expedited pathways, and emerging development trends for pharmaceutical and biotech companies.
This executive summary provides a high-level overview of the most important EMA approvals and regulatory developments from 2025, including Conditional Marketing Authorisations (CMAs), PRIME designations, accelerated assessments, orphan medicines, and approvals under exceptional circumstances. The full downloadable resource includes detailed analysis and product-specific insights for drug developers navigating the EU market, including full indication statements, pivotal data summaries, approval notes, and more.
2025 EMA medicine approvals at a glance
In 2025, the EMA authorised 38 new active substances across a wide range of therapeutic areas. Several medicinal products benefited from expedited regulatory pathways designed to accelerate patient access to innovative medicines:
- 6 medicines received support through the EMA’s PRIority MEdicines (PRIME) scheme
- 16 orphan-designated medicines received approval
- 8 Conditional Marketing Authorisations (CMAs) were granted
- 3 products received accelerated assessment
- 2 marketing authorisations under exceptional circumstances were approved
For pharmaceutical and biotech companies developing innovative therapies, these approvals demonstrate the EMA’s continued focus on accelerating access to treatments addressing unmet medical needs.
Oncology continues to dominate EMA medicine approvals
Oncology remained the leading therapeutic area in 2025, accounting for 14 new medicine approvals. Interesting approvals included:
- Anktiva
- Aucatzyl
- Datroway
- Lynozyfic
- Voranigo
- Ziihera
The strong representation of oncology products highlights the ongoing regulatory momentum for cell and gene therapies, targeted therapies, antibody-drug conjugates, and precision oncology medicines within the EU.
Conditional Marketing Authorisation (CMA): Accelerating access to innovation
Conditional Marketing Authorisation remains a critical regulatory pathway for companies developing medicines for serious or life-threatening diseases, where there is a high unmet medical need.
In 2025, 8 medicines received CMA approval, including therapies for:
- Relapsed or refractory cancers
- Duchenne muscular dystrophy
- Metabolically-dysfunction-associated steatohepatitis (MASH)
- Rare haematological malignancies
Several approvals were supported by data from single-arm Phase 1/2 clinical trials, reinforcing the importance of strong efficacy signals and carefully designed development programmes for biotech and pharmaceutical sponsors pursuing accelerated pathways.
Accelerated Assessment: Faster EMA review timelines
The EMA granted accelerated assessment to three medicines in 2025:
- Brinsupri
- Vimkunya
- Yeytuo
Accelerated assessment reduces CHMP review timelines from 210 days to 150 days and is reserved for products considered of major public health interest or therapeutic innovation.
For regulatory affairs teams and biotech companies planning EU submissions, understanding eligibility criteria for accelerated assessment is increasingly important when developing global regulatory strategies.
PRIME Scheme: Early regulatory support for innovative medicines
The EMA’s PRIME scheme continued to play a significant role in supporting innovative medicines in 2025. Products benefiting from PRIME included therapies for:
- Rare cancers
- Non-cystic fibrosis bronchiectasis
- Type 1 diabetes
- Rare dermatological diseases
- Vaccines for emerging infectious diseases
PRIME provides early scientific and regulatory support to optimise development plans and improve the quality of evidence submitted at the time of marketing authorisation application (MAA).
For emerging biotech companies, PRIME designation can significantly strengthen regulatory interactions and support accelerated approval opportunities in Europe.
Orphan Drug Designation remains important
A total of 16 orphan-designated medicinal products received EMA approval in 2025.
While orphan designation offers substantial incentives for rare disease medicine developers, maintaining orphan status during the MAA process can be challenging. Sponsors are expected to provide robust quantitative evidence supporting prevalence assumptions and significant benefit claims.
This reinforces the importance of early regulatory planning and integrated orphan drug strategy development for biotech and pharmaceutical companies targeting rare diseases.
Marketing authorisation under exceptional circumstances
Two new active substances received approval under exceptional circumstances in 2025:
- Imreplys
- Maapliv
This pathway is reserved for situations where comprehensive efficacy and safety data cannot reasonably be obtained, often due to ultra-rare indications or ethical limitations in data collection.
Download the full EMA 2025 medicine approvals report
Our full resource provides a comprehensive breakdown of all 2025 EMA approvals, including regulatory pathways, therapeutic trends, product-specific details, and insights for pharmaceutical, biotech, and regulatory affairs professionals.
How Somerville Development Partners can help
Our team brings decades of combined experience across both consultancy and industry settings. This dual perspective enables us to balance regulatory rigour with scientific and operational realities. We don’t just advise, we embed within your team to deliver high-quality regulatory solutions to help pharmaceutical and biotech companies develop safe and efficacious medicines for patients.
Whatever your needs, we are your trusted life sciences partner:
- Short-term (3–6 months), discrete projects to address a particular need for resources or expertise.
- Long-term (12–24 months) projects, such as an MAA, new drug application or biologics license application.
- Ad-hoc or complex development services such as regulatory due diligence, paediatric development or orphan designation if you are developing medicines for rare diseases.